<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36705279</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2376-1032</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of managed care &amp; specialty pharmacy</Title><ISOAbbreviation>J Manag Care Spec Pharm</ISOAbbreviation></Journal><ArticleTitle>The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council.</ArticleTitle><Pagination><StartPage>216</StartPage><EndPage>221</EndPage><MedlinePgn>216-221</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18553/jmcp.2023.29.2.216</ELocationID><Abstract><AbstractText><b>DISCLOSURES:</b> Funding for this summary was contributed by Blue Cross Blue Shield of MA, California Healthcare Foundation, The Patrick and Catherine Weldon Donaghue Medical Research Foundation, Arnold Ventures, and Kaiser Foundation Health Plan Inc., to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, America's Health Insurance Plans, AbbVie, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy Solutions, Express Scripts, Genentech/ Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, Health First, Health Partners, Humana, Johnson &amp; Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer. Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, Sun Life Financial, uniQure, and United Healthcare. Mr Nikitin, Ms McKenna, Ms Richardson, and Drs Rind and Pearson are employed by ICER. Through their affiliated institutions, Drs Makam, Carlson, and Suh received funding from ICER for the work described in this summary.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nikitin</LastName><ForeName>Dmitriy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Clinical and Economic Review, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makam</LastName><ForeName>Anil N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Division of Hospital Medicine, San Francisco General Hospital, University of California and Philip R Lee Institute for Health Policy Studies, University of California San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suh</LastName><ForeName>Kangho</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University of Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenna</LastName><ForeName>Avery</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Clinical and Economic Review, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Josh J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Clinical and Economic Review, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rind</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Institute for Clinical and Economic Review, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>Steven D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Institute for Clinical and Economic Review, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Manag Care Spec Pharm</MedlineTA><NlmUniqueID>101644425</NlmUniqueID><ISSNLinking>2376-0540</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000723627">sodium phenylbutyrate and taurursodiol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="Y">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Funding for this summary was contributed by Blue Cross Blue Shield of MA, California Healthcare Foundation, The Patrick and Catherine Weldon Donaghue Medical Research Foundation, Arnold Ventures, and Kaiser Foundation Health Plan Inc., to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER&#x2019;s annual policy summit is supported by dues from Aetna, America&#x2019;s Health Insurance Plans, AbbVie, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy Solutions, Express Scripts, Genentech/ Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, Health First, Health Partners, Humana, Johnson &amp; Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer. Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, Sun Life Financial, uniQure, and United Healthcare. Mr Nikitin, Ms McKenna, Ms Richardson, and Drs Rind and Pearson are employed by ICER. Through their affiliated institutions, Drs Makam, Carlson, and Suh received funding from ICER for the work described in this summary.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>27</Day><Hour>7</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36705279</ArticleId><ArticleId IdType="pmc">PMC10387989</ArticleId><ArticleId IdType="doi">10.18553/jmcp.2023.29.2.216</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162-72. doi:10.1056/NEJMral603471</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wit J, Bakker LA, van Groenestijn AC, et al. . Caregiver burden in amyotrophic lateral sclerosis: A systematic review. Palliat Med. 2018;32(1):231-45. doi:10.1177/0269216317709965</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5784458</ArticleId><ArticleId IdType="pubmed">28671483</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Raymond J, Punjani R, et al. . Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017. Amyotroph Lateral Scler Frontotemporal Degener. 2022:1-9. doi:10.1080/21678421.2022.205 9380</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9568617</ArticleId><ArticleId IdType="pubmed">35422180</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et al. . Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218-26. doi:10.1212/WNL.0b013e3181bc0141</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764727</ArticleId><ArticleId IdType="pubmed">19822872</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Nicholson K, Leigh F, et al. . Developing multidisciplinary clinics for neuromuscular care and research. Muscle Nerve. 2017;56(5):848-58. doi:10.1002/mus.25725</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5656914</ArticleId><ArticleId IdType="pubmed">28632945</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012(3):CD001447. doi:10.1002/14651858.CD001447.pub3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Radicava ORS (oral suspension). [Package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC. Accessed May 13, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215446s000lbl.pdf</Citation></Reference><Reference><Citation>US Food and Drug Administration. RELYVRIO (oral suspension). [Package insert]. Amylyx Pharmaceuticals, Inc; 2022. Accessed September 29, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216660s000lbledt.pdf</Citation></Reference><Reference><Citation>Institute for Clinical and Economic Review. AMX0035 and oral edaravone for amyotrophic lateral sclerosis. Accessed September 29, 2022. https://icer.org/wp-content/uploads/2022/02/ICER-ALS-Final-Report-09132022.pdf</Citation></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. . Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919-30. doi:10.1056/NEJMoa1916945</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, et al. . Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31-9. doi:10.1002/mus.27091</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Drug Evaluation and Research. AMX0035 clinical overview and statistical review. Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) Meeting. Accessed March 30, 2022. https://www.fda.gov/media/157186/download</Citation></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, et al. . Confirmatory double-blind, parallelgroup, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7-8):610-7. doi:10.3109/21678421.2014.959024</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group on Behalf of the Edaravone (MCI-186) ALS 17 Study Group. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):408. doi:10.1080/21678421.2017.1361441</Citation><ArticleIdList><ArticleId IdType="pubmed">28872915</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-12. doi:10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Genge A, Pattee GL, Sobue G, et al. . 24-week results from phase 3 study MT-1186-A01 an open-label, multicenter safety study of oral edaravone in subjects with amyotrophic lateral sclerosis (P1-13.001). Neurology. 2022;98(18 Supplement):1199.</Citation></Reference><Reference><Citation>ClinicalTrials.gov. Phase III trial of AMX0035 for amyotrophic lateral sclerosis treatment (Phoenix). Accessed September 29, 2022. https://clinicaltrials.gov/ct2/show/NCT05021536</Citation></Reference><Reference><Citation>US Food and Drug Administration. Radicava (edaravone injection). [Package insert]. Jersey City, NJ: Mitsubishi Tanabe Pharma Corporation. Accessed September 29, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209176s010lbl.pdf</Citation></Reference><Reference><Citation>Witzel S, Maier A, Steinbach R, et al. . Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79(2):121-30. doi:10.1001/jamaneurol.2021.4893</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8749709</ArticleId><ArticleId IdType="pubmed">35006266</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute for Clinical and Economic Review. ICER&#x2019;s reference case for economic evaluations: Principles and rationale. Accessed September 29, 2022. https://icer.org/wp-content/uploads/2020/10/ICER_Reference_Case_013120.pdf</Citation></Reference><Reference><Citation>CADTH CAfDaTiH. CADTH Common Drug Review: Clinical review report - edaravone (RADICAVA). Accessed September 29, 2022. https://www.cadth.ca/sites/default/files/cdr/clinical/sr0573-radicava-clinical-review-report.pdf</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>